Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced BRAF Mutant Cancers”

35 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 35 results

Early research (Phase 1)Ended earlyNCT06194877
What this trial is testing

Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Who this might be right for
Colorectal CancerPancreatic Ductal CancerAdvanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
MapKure, LLC 13
Testing effectiveness (Phase 2)Study completedNCT03843775
What this trial is testing

Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Who this might be right for
Advanced BRAF Mutant Cancers
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)UnknownNCT04653480
What this trial is testing

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Who this might be right for
Colorectal Cancer
Zhejiang University 61
Large-scale testing (Phase 3)Study completedNCT01689519
What this trial is testing

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 495
Testing effectiveness (Phase 2)UnknownNCT05370807
What this trial is testing

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

Who this might be right for
Melanoma Stage IIIMelanoma Stage IV
Universitair Ziekenhuis Brussel 48
Very early researchActive Not RecruitingNCT03543969
What this trial is testing

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Who this might be right for
Melanoma (Skin)Skin CancerSkin Melanoma+1 more
H. Lee Moffitt Cancer Center and Research Institute 14
Early research (Phase 1)Study completedNCT03415126
What this trial is testing

ASN007 in Patients With Advanced Solid Tumors

Who this might be right for
CancerMalignancyNeoplasia+16 more
Asana BioSciences 49
Testing effectiveness (Phase 2)Ended earlyNCT03580382
What this trial is testing

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Who this might be right for
Melanoma
NYU Langone Health 3
Large-scale testing (Phase 3)WithdrawnNCT02427893
What this trial is testing

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Who this might be right for
Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Large-scale testing (Phase 3)Ended earlyNCT02967692
What this trial is testing

The Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 568
Testing effectiveness (Phase 2)WithdrawnNCT02109653
What this trial is testing

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer
Early research (Phase 1)Ended earlyNCT02974725
What this trial is testing

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Who this might be right for
Non-Small Cell Lung CancerMelanoma
Novartis Pharmaceuticals 241
Testing effectiveness (Phase 2)Study completedNCT01512251
What this trial is testing

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

Who this might be right for
BRAF Mutant Metastatic Melanoma
University of California, San Francisco 8
Testing effectiveness (Phase 2)Study completedNCT04059224
What this trial is testing

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

Who this might be right for
Stage IV MelanomaStage III Melanoma
Universitair Ziekenhuis Brussel 45
Testing effectiveness (Phase 2)Looking for participantsNCT07789210
What this trial is testing

A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases

Who this might be right for
Colorectal CancerBRAF V600E Mutation PositiveEncorafenib+1 more
Zhejiang University 25
Testing effectiveness (Phase 2)Ended earlyNCT01616199
What this trial is testing

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Who this might be right for
Advanced BRAF-mutant Cancers
Cascadian Therapeutics Inc. 24
Early research (Phase 1)Study completedNCT05003622
What this trial is testing

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Who this might be right for
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Pierre Fabre Medicament 3
Early research (Phase 1)Active Not RecruitingNCT05538130
What this trial is testing

Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Who this might be right for
MelanomaGliomaThyroid Cancer+10 more
Pfizer 148
Early research (Phase 1)UnknownNCT03781219
What this trial is testing

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Who this might be right for
Solid Tumor
Shanghai Kechow Pharma, Inc. 45
Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Next Page